<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6315">
  <stage>Registered</stage>
  <submitdate>1/02/2017</submitdate>
  <approvaldate>1/02/2017</approvaldate>
  <nctid>NCT03053102</nctid>
  <trial_identification>
    <studytitle>A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)</studytitle>
    <scientifictitle>A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of ACH-0144471 in Untreated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-002652-25</secondaryid>
    <secondaryid>ACH471-100</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Paroxysmal Nocturnal Hemoglobinuria (PNH)</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ACH-0144471

Experimental: ACH-0144471 - All patients will receive ACH-0144471 during the treatment period.


Treatment: drugs: ACH-0144471
ACH-0144471 will be administered to all patients enrolled in the study.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change-from-baseline in serum lactate dehydrogenase (LDH) levels</outcome>
      <timepoint>Day 28</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change-from-baseline in hemoglobin (Hgb)</outcome>
      <timepoint>At Day 28 and Day 84</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serious Adverse Events (SAEs), Grade 3 and Grade 4 Adverse Events (AEs), and AEs leading to discontinuation</outcome>
      <timepoint>Up to 15 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Grade 3 and Grade 4 laboratory abnormalities</outcome>
      <timepoint>Up to 15 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Profile of Pharmacokinetics: Area under the curve (AUC)</outcome>
      <timepoint>Up to Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Profile of Pharmacokinetics: Maximum plasma concentration (Cmax)</outcome>
      <timepoint>Up to Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Profile of Pharmacokinetics: Time to maximum concentration (Tmax)</outcome>
      <timepoint>Up to Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Profile of Pharmacodynamics: Complement pathway biomarkers (AP-Wieslab, factor D, and Bb)</outcome>
      <timepoint>Up to Day 28</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Study designed to include 4 to 12 male and female patients age 18 years or older

          -  Currently untreated PNH patients with PNH Type III erythrocyte and/or granulocyte
             clone size = 10% and anemia (Hgb &lt; 12g/dL) with adequate reticulocytosis (as
             determined by the investigator)

          -  Lactate dehydrogenase (LDH) = 1.5X the upper limit of normal (ULN)

          -  Platelets = 50,000/uL without the need for platelet transfusions

          -  Documentation of vaccination for N. meningitidis (quadrivalent ACWY and serogroup B),
             H. influenza, and S. pneumoniae, or willingness to receive vaccinations during the
             screening period

          -  Negative pregnancy test for females prior to dosing and throughout the study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of a major organ transplant (e.g., heart, lung, kidney, liver) or
             hematopoietic stem cell/marrow transplant

          -  Patients who have received another investigational agent within 30 days or 5
             half-lives of the investigational agent prior to study entry, whichever is greater

          -  Patients who have received eculizumab at any dose or interval within the past 75 days
             before study entry

          -  Patients with known or suspected complement deficiency

          -  Patients with active bacterial infection or clinically significant active viral
             infection, a body temperature &gt; 38Â°C, or other evidence of infection on Day 1, or with
             a history of febrile illness within 14 days prior to first study drug administration

          -  History of meningococcal infection, or a first-degree relative or household contact
             with a history of meningococcal infection

          -  Females who are pregnant, nursing, or planning to become pregnant during the study or
             within 90 days of study drug administration or patients with a female partner who is
             pregnant, nursing, or planning to become pregnant during the study or within 90 days
             of study drug administration</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>31/03/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/05/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Achillion Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the safety and effectiveness of ACH-0144471 in
      currently untreated patients with PNH. This study is designed to include 4 to 12 patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03053102</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>John Lahey</name>
      <address />
      <phone>+1 203-752-5437</phone>
      <fax />
      <email>jlahey@achillion.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>